(E)-but-2-enedioic acid di-tert-butoxy-phosphoryloxymethyl ester methyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: (E)-but-2-enedioic acid di-tert-butoxy-phosphoryloxymethyl ester methyl ester
• 英文别名: 4-O-[bis[(2-methylpropan-2-yl)oxy]phosphoryloxymethyl] 1-O-methyl (E)-but-2-enedioate
• 化学式: C₁₄H₂₅O₈P
• 分子量: 352.32
• InChiKey: YOAZKHLOZSKKBU-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  23
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  97.4
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  三乙胺 、 Di-tert-butyl phosphate 、 chloromethyl methyl fumarate 在 氮气 、 乙酸乙酯 、 水 、 碳酸氢钠 、 Brine 、 magnesium sulfate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 (E)-but-2-enedioic acid di-tert-butoxy-phosphoryloxymethyl ester methyl ester
  参考文献：
  名称：

  PRODRUGS OF MONOMETHYL FUMARATE (MMF)

  摘要：

  本发明涉及新型化合物作为药物的用途。具体而言，本发明涉及新型丙烯酸单甲酯（MMF）的前药，适用于药物，优选用于治疗和/或预防全身性疾病，自身免疫性疾病，炎症性疾病，例如多发性硬化和牛皮癣。

  公开号：

  US20150299103A1

文献信息

• PRODRUGS OF MONOMETHYLFUMARATE (MMF)
  申请人：ratiopharm GmbH

  公开号：EP3243511A1

  公开（公告）日：2017-11-15

  The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis.

  本发明涉及可用作药物的新型化合物。特别是，本发明涉及适用于治疗和/或预防全身性疾病、自身免疫性疾病、炎症性疾病（如多发性硬化症和牛皮癣）的富马酸单甲酯（MMF）的新型原药。
• METHODS OF TREATING MULTIPLE SCLEROSIS
  申请人：Biogen MA Inc.

  公开号：EP3804711A1

  公开（公告）日：2021-04-14

  Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.

  本文提供了用富马酸盐治疗多发性硬化症的方法，其中富马酸盐是富马酸二烷基酯、富马酸单烷基酯、富马酸二烷基酯和富马酸单烷基酯的组合、富马酸单烷基酯的原药、前述任一物质的氚化形式、或前述任一物质的药学上可接受的盐、凝胶体、溶胶体、同系物或立体异构体、或前述任一物质的组合。本文提供的方法通过告知和监测接受治疗的患者进行性多灶性白质脑病的情况，和/或通过监测淋巴细胞计数，提高了治疗的安全性。
• Methods of Treating Multiple Sclerosis
  申请人：Biogen MA Inc.

  公开号：US20170354630A1

  公开（公告）日：2017-12-14

  Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
• US9868690B2
  申请人：——

  公开号：US9868690B2

  公开（公告）日：2018-01-16
• [EN] PRODRUGS OF MONOMETHYL FUMARATE (MMF)<br/>[FR] PROMÉDICAMENTS DE FUMARATE DE MONOMÉTHYLE (MMF)
  申请人：RATIOPHARM GMBH

  公开号：WO2014096425A2

  公开（公告）日：2014-06-26

  The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis.